Product image of Maexeni 30 Mite (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Maexeni 30 Mite

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Maexeni 30 Mite (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Maexeni 30 Mite, are a combined oral contraceptive presented as a tablet for oral use. They prevent pregnancy in women of reproductive age.
GNH India supplies Maexeni 30 Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hormosan Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maexeni 30 Mite is a combined oral contraceptive that acts on the reproductive hormone pathway to prevent pregnancy.

  • Contraception: provides reliable prevention of pregnancy for women of child‑bearing age.
  • Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.
  • Hormonal acne management: may improve moderate acne associated with androgen excess.

How It Works

  • Ethinylestradiol and Levonorgestrel work together to suppress the hypothalamic‑pituitary‑gonadal axis, inhibiting the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone. This prevents ovulation, while the progestin component thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation.

Side Effects

Maexeni 30 Mite may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like.
  • Breast tenderness: temporary swelling or discomfort.
  • Spotting or breakthrough bleeding: irregular light bleeding.
  • Weight change: slight increase or decrease.
  • Mood changes: irritability or mood swings.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in legs.
  • Pulmonary embolism: clot migration to lungs.
  • Stroke or transient ischemic attack.
  • Hepatic adenoma or other liver tumors.
  • Severe allergic reaction: rash, swelling, anaphylaxis.
  • Hypertension: significant rise in blood pressure.

Precautions & Warnings

Before prescribing Maexeni 30 Mite, clinicians should evaluate individual risk factors and counsel patients on safe use.

  • Cardiovascular assessment: avoid in women with history of thromboembolic disease.
  • Smoking restriction: do not smoke if over 35 years of age.
  • Liver function: contraindicated in severe hepatic impairment.
  • Blood pressure monitoring: check regularly during therapy.
  • Missed dose guidance: provide clear instructions for forgotten tablets.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Avoid Interactions

Maexeni 30 Mite can interact with several medicines that alter hormone metabolism or increase clotting risk.

Major Interactions (Avoid)

  • Rifampin and other potent enzyme inducers: reduce contraceptive efficacy.
  • Antiepileptic drugs (carbamazepine, phenytoin, phenobarbital): lower hormone levels.
  • St. John's Wort: may diminish contraceptive effect.
  • Certain HIV protease inhibitors: unpredictable hormone concentrations.
  • Griseofulvin: decreases oral contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (ketoconazole, itraconazole): may increase hormone levels.
  • Selective serotonin reuptake inhibitors: potential for increased bleeding.
  • Diuretics (thiazides): may affect fluid balance.
  • Antihypertensives (ACE inhibitors): monitor blood pressure.
  • Herbal supplements (ginkgo biloba): watch for additive clotting effects.

Frequently Asked Questions

Maexeni 30 Mite is a combined oral contraceptive tablet containing Ethinylestradiol and Levonorgestrel. It is prescribed to prevent pregnancy in women of reproductive age by inhibiting ovulation and creating conditions that are unfavorable for fertilisation and implantation.

Ethinylestradiol, the estrogen component, suppresses the release of gonadotropins from the pituitary gland, which prevents the mid‑cycle surge of luteinising hormone that triggers ovulation. Together with Levonorgestrel, it also thickens cervical mucus and alters the endometrium, reducing the chance of implantation.

The dosing regimen for Maexeni 30 Mite is determined by the prescribing healthcare professional. Typically, the product is taken once daily for a defined cycle, but the exact schedule, including any hormone‑free interval, must be individualized by the prescriber.

Maexeni 30 Mite is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be stopped immediately. Use during breastfeeding should be discussed with a healthcare provider, as hormonal contraceptives can affect milk production and infant exposure.

To order Maexeni 30 Mite, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Maexeni 30 Mite contains the widely used estrogen‑progestin pair of Ethinylestradiol and Levonorgestrel, offering a well‑characterised efficacy and safety profile comparable to other second‑generation combined oral contraceptives. Differences among products generally relate to hormone dose, pill regimen (21/7 vs 24/4), and specific brand formulations.

Store Maexeni 30 Mite tablets at ambient temperature, below 25 °C. Keep the blister pack in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Maexeni 30 Mite is taken orally, usually with water, once each day at the same time. The tablet should be swallowed whole and not chewed or broken. Patients should follow the specific cycle instructions provided by their prescriber.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Additional rare but severe concerns are hepatic adenoma, severe hypertension, and allergic reactions that may lead to anaphylaxis. Prompt medical attention is required if any of these symptoms occur.

Women with a history of venous or arterial thromboembolism, known or suspected estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or who are smokers over 35 years of age should avoid Maexeni 30 Mite. Contraindications also include pregnancy and known hypersensitivity to any component of the tablet.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT